Upload
homer-simmons
View
216
Download
0
Tags:
Embed Size (px)
Citation preview
New Regimens to Prevent Tuberculosis in Adults with HIV Infection
Neil A. Martinson, Grace L. Barnes, Lawrence H. Moulton, Reginah Msandiwa, Harry Hausler, Malathi Ram, et al.
N Engl J Med 2011;365:11-20.
Presented By:
Vikash Keshri
Introduction:
• Tuberculosis; most common opportunistic infection, leading
cause of death among HIV Infected.
• Preventive treatment with Isoniazid for 6 to 12 months or a
combination of Isoniazid + Rifampin for 3 months reduces the
risk of tuberculosis by 32 to 64%. (Whalen CC et al).
• WHO policy recommend use of Isoniazid for 6 months.
• Concerns for low completion rates, the potential for re-
infection and selection of drug-resistant mycobacterium
strains deter public health programs to implement preventive
treatment widely.
Learning Objective
• To learn about Randomized Controlled Trial.
• Kaplan- Meir Method of Survival Analysis.
Objective of study:
• To Evaluate 3 new regimen for latent Tuberculosis in patients
with HIV Infection.
• 12 Weeks course of Rifapentine (900 mg.) given Weekly or
Rifampin (600 mg.) given twice weekly both with Isoniazid (900 mg).
• Continuous Isoniazid (300 mg.) daily for duration of study (≤ 6
Years).
• Compared to Control regimen of Isoniazid (300 mg.) daily for 6
Months.
Methodology
• Study Design:Open- label, Randomized controlled trial
• Study Area:
Soweto, South Africa, a community with high prevalence of HIV and TB.
• Study Subjects:
HIV infected adults (>18 yrs.), ≥ 5 mm. induration on TST screened. Eligibility Criteria:– Not Pregnant or Lactating.– No active Tuberculosis (Symptoms/CXR or Culture).– Not received TB treatment > 2 months in past.– On Anti retro viral Therapy.– CD4 count < 200 / Cu mm.
Methodology Cont…
• Ethical Clearance:– By IRB, Johns Hopkins Medicine, University of Witwatersrand,
FDA and Medicine control council of South Africa.– Written Informed Consent taken
• Treatment Group and Administration:
3 treatment group and 1 Control group.
Treatment for Rifapentine and Rifampin with INH were Observed
Isoniazid daily and Isoniazid continuous treatment self administered
25 Mg. Pyridoxine with each ATT dose.
• Randomization:
Block randomization in 2:2:2:1 ratio with computer generated algorithm.
Study Procedure:
• Follow Up:– During treatment
• Once weekly for Rifapentine +INH group.• Twice weekly for Rifampin + INH group.• Every 2 Weeks for Isoniazid 6 moths and cont. Isoniazid
group.
– After treatment completion• Monthly for continuous Isoniazid group• Every 6 Months for treatment completed or discontinue.
Follow Up
• Symptoms/ Signs of TB
Yes No
Sputum Smear
Mycobacterium culture
& Sensitivity
Chest X ray• AST and ALT level at 1,2 and 6 months then 6 monthly.• CD4 Count 6 monthly and 3 monthly for (CD4<350) initially.• Patient eligible for ART referred to ART centre but remained in
study.• Women becoming pregnant switched to 6 months Isoniazid group.• All discontinuing patients were followed up.
Study End Point
Primary: Tuberculosis free survival. Changed to TB or Death on recommendation of safety monitoring board
Secondary: Adherence to study regimen, adverse events, discontinuation, Drug Resistance.
Case Definitions:
Confirmed TB: Sign/Symptoms and culture positive from any site.
Probable TB: Sign/Symptoms and AFB in Sputum smear or caseous necrosis in tissue biopsy.
Possible TB: Sign/Symptoms without microbiological or histological evidence but responding to ATT.
Clinical record or Death Certificate obtained. Independent Committee reviewed all End Point.
Statistical Analysis:
• Intention to treat analysis of Primary End Point (Included patient of Confirmed, Probable or Possible TB or Death)
• As treated analysis for patient who received treatment > 2 months and didn’t had TB for 3 months after randomization.
Results:
Table 1. Baseline Characteristics of the Study Patients, According to Treatment Group.
Characteristic Rifapentine withIsoniazid Weeklyfor 12 Wk(N = 328)
Rifampin withIsoniazid TwiceWeekly for 12 Wk(N = 329)
Isoniazid Dailyfor ≤6 Yr(N = 164)
Isoniazid Dailyfor 6 Mo(N = 327)
All Patients(N = 1148)
Female sex no. (%)
277 (84.5)
267 (81.2) 139 (84.8) 273 (83.5) 956 (83.3)
Age in Years
Median 30.3 30.5 30.2 30.5 30.4
Inter quartile range
26.3–35.0
27.0–34.3 25.4–34.2 26.3 – 34.9 26.4–34.7
Black Race No. (%)
325 (99.1)
327 (99.4) 163 (99.4) 327 (100.0) 1142 (99.5)
≥12 Yr of schooling no. (%)
93 (28.4) 102 (31.0) 61 (37.2) 117 (35.8) 373 (32.5)
Formal employment no. (%)
40 (12.2) 34 (10.3) 12 (7.3) 39 (11.9) 125 (10.9)
Imprisoned before enrollment no. (%)
48 (14.6) 52 (15.8) 21 (12.8) 40 (12.2) 161 (14.0)
Diameter of induration
Median 14.5 15.0 15.0 15.0 15.0
I – Q Range 12-19 12-19 12-19 11-18 15.0
CD4 count: cells/mm3
Median 471 498 476 490 484
I-Q Range 352–666 353–696 346–644 340–670 350–672
Viral load — log10 copies/ml
Median 4.3 4.0 4.2 4.2 4.2
I- Q Range
3.6–4.8 3.4–4.7 3.6–4.7 3.6–4.7 3.6–4.7
BMI Median 25.0 24.7 25.3 24.9 24.9
I- Q Range
21.8–29.2 21.9–28.4 22.6–29.3 22.1–29.5 22.1–29.0
Table 2. Rates of Study End Points According to Treatment Group.*
End Point Rifapentine–Isoniazid
Rifampin–Isoniazid
Continuous Isoniazid
6-Mo Isoniazid
All
Tuberculosis
No. of cases 24 24 8 22 78
Person-yr of follow-up 1187.5 1219.7 561.0 1143.9 4112.1
Incidence rate per 100 person-yr
2.0 2.0 1.4 1.9 1.9
Death
No. of cases 17 16 8 25 66
Person-yr of follow-up 1223.6 1269.8 574.2 1180.0 4247.6
Incidence rate per 100 person-yr
1.4 1.3 1.4 2.1 1.6
Death or TB
No. of cases 37 35 15 41 128
Person-yr of follow-up 1187.5 1219.7 561.0 1143.9 4112.1
Incidence rate per 100 person-yr
3.1 2.9 2.7 3.6 3.1
P values are for the comparison with the 6-month regimen of Isoniazid.
Tuberculosis
Crude incidence-rate ratio (95% CI)
1.05 (0.56–1.97)
1.02 (0.55–1.91)
0.74 (0.29–1.73)
Reference 1.0
P value 0.87 0.94 0.48
Death
Crude incidence-rate ratio (95% CI)
0.66 (0.33–1.26)
0.59 (0.30–1.16)
0.66 (0.26–1.50)
Reference 1.0
P value 0.18 0.10 0.31
Death or tuberculosis
Crude incidence-rate ratio (95% CI)
0.87 (0.54–1.39)
)0.80 (0.50–1.29)
0.75(0.38–1.38)
Reference 1.0
P Value 0.54 0.34 0.34
Discussion:
• The overall rate of tuberculosis was 1.9 cases per 100 person-
years.
• No significant difference between any of the three new regimens
and the control regimen.
• The expected annual rate of tuberculosis ranges from 5 and 10%.
• The shorter, Rifampin-based regimens had higher adherence rates
than 6-month Isoniazid.
• Twice weekly regimen of Rifampin + INH is efficacious.
• No clinically significant safety concern identified with Once- Weekly
Rifapentine and Isoniazid
Discussion Cont …
• No additional benefit of continuous Isoniazid as compared with 6
months of Isoniazid as preventive treatment.
• Post hoc as treated analyses suggest that continuous Isoniazid was
effective.
• Cox Proportional Hazard Analysis Shows 58% less risk of TB or
Death among Cont. Isoniazid group ( P value = 0.02)
• But rate of TB increased markedly after treatment stopped.
Other Evidences:
Whalen CC, et al. N Engl J Med 1997;337:801-8.
A trial of three regimens to prevent tuberculosis in Ugandan adults infected with the human immunodeficiency virus
Randomized Placebo Controlled Trial
6 month Isoniazid confers short term protection.Multidrug regimen of Rifampin +INH for 3 Months is also Effective
Pape JW, et al. Lancet1993;342:268-72.
Effect of Isoniazid prophylaxis on incidence of active tuberculosis and progression of HIV infection
Randomized Controlled Trial
Incidence of tuberculosis lower in Isoniazid recipients.
Mwinga A, et al..AIDS 1998;12:2447-57.
Twice weekly tuberculosis preventivetherapy in HIV infection in Zambia
Randomized Double-blind Placebo-Controlled Trial
Twice Weekly Isoniazid for 6 months or Rifampicin + Pyrazinamide for3 months reduced incidence.
Other Evidences cont..Bucher HC, et al.AIDS 1999, 13:501–507
Isoniazid prophylaxis for tuberculosis in HIV infection:a meta-analysis of randomized controlled trials
Meta-analysis of Randomized Controlled trials.
INH for 6 months effectively reduces the incidence. StatisticallySignificant.
Volmink J, Woldehanna S.Cochrane Database Syst Rev 2010;1:CD000171.
Treatment of latent tuberculosis infection in HIV infectedpersons (Review)
11 trials were included with a total of 8,130 randomized participants.
Preventive therapy (any anti-TB drug) versus placebo lower incidence of active tuberculosis (RR 0.64, 95% CI 0.51 to 0.81).
Samandari T, et al.Lancet 2011; 377: 1588–98
6-month versus 36-month Isoniazid preventive treatmentfor tuberculosis in adults with HIV infection in Botswana.
Randomized, Double-blind, Placebo-Controlled trial
In endemic area 36 months’ isoniazid more effective than 6-month.
Conclusions:
• Short-course, Rifampin-based preventive treatment had similar, not
superior, efficacy to 6 months of Isoniazid in tuberculin-positive
adults infected with HIV.
• Use of these regimens in clinical practice could substantially
increase the number of patients who receive and complete
preventive therapy.
• More widespread use of preventive therapy, regardless of the
regimen chosen, is essential to help control the epidemic of HIV
related tuberculosis.
Comments:
• Report of trial confers to CONSORT Statement: (Except Some issue ???)– Blinding not done – Participants flow not properly described.
• Recruitment time
• Outcome Measured – TB or Death (cause of Death not evaluated).
• Role of other covariates or confounders for Death not seen.
• Ideally Induration > 10 mm. considered +ve (≥ 5 mm in study)
• Why 83% Women included in the trial.